Mesothelioma Treatment
Mesothelioma Cancer
- Causes of Mesothelioma
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
- Mesothelioma Treatment
- Innovative Mesothelioma Treatments
- Managing Mesothelioma Pain
- Nutrition Information for Mesothelioma Patients
- Specialized Mesothelioma Care
- Mesothelioma Risks
- Mesothelioma Support Groups
- Find a Mesothelioma Attorney
- Mesothelioma News
Mesothelioma Directory
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Get Help Today
Looking for help or additional information? Contact us today.| Conditions: | Mesothelioma |
| Start Date: | February 1, 2004 |
| Phase: | Phase II |
| Status: | Active, not recruiting |
| NCT ID: | NCT00137826 |
| Study Type: | Interventional |
| Intervention: | Drug: Erlotinib/Drug: Bevacizumab |
| Study Design: | Treatment/Non-Randomized/Open Label/Uncontrolled/Single Group Assignment/Efficacy Study |
| Results: | No Results Available |
| Sponsors: | Dana-Farber Cancer Institute/Massachusetts General Hospital/University of Chicago |
| Ages: | Adult/Senior |
| Enrollment: | 37 |
| Funded By: | OTHER |
| First Received: | August 29, 2005 |
| End Date: | March 1, 2009 |
| Last Updated: | December 20, 2007 |
| Last Verified: | December 1, 2007 |